SCHEMBL676819

SCHEMBL676819

O=c1[nH]c(-c2ccc3[nH]c4nc(Cl)ccc4c3c2)cs1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.49
BRD4 O60885 16/20 0.48
KDM4E B2RXH2 1/20 0.44
GMNN O75496 1/20 0.44
LMNA P02545 1/20 0.44
CYP1A2 P05177 1/20 0.44
PKM P14618 1/20 0.44
TSHR P16473 1/20 0.44
ADORA2A P29274 1/20 0.44
ADORA1 P30542 1/20 0.44
CYP2C19 P33261 1/20 0.44
MTOR P42345 1/20 0.44
BLM P54132 1/20 0.44
PMP22 Q01453 1/20 0.44
HIF1A Q16665 1/20 0.44
HSD17B10 Q99714 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL675881 0.85 ADORA2A (0.45) ALDH1A1BRD4ADORA2AADORA1
SCHEMBL675161 0.80 ALDH1A1 (0.52) ALDH1A1BRD4SMN1; SMN2
SCHEMBL676408 0.78 BRD4 (0.48) ALDH1A1BRD4ADORA2AADORA1SMN1; SMN2
SCHEMBL676516 0.77 ROCK2 (0.48) ALDH1A1KDM4ELMNAHSD17B10SMN1; SMN2
SCHEMBL676158 0.76 ALK (0.50) ALDH1A1BRD4SMN1; SMN2
SCHEMBL675919 0.75 KDM4E (0.54) KDM4EGMNNLMNACYP1A2PKM
SCHEMBL676125 0.72 GRIN2D (0.45) ALDH1A1KDM4EGMNNLMNACYP1A2
SCHEMBL3671601 0.71 ALK (0.46) ALDH1A1KDM4ETSHRHSD17B10SMN1; SMN2
SCHEMBL675640 0.70 PIM3 (0.45) ALDH1A1KDM4EGMNNLMNACYP1A2
SCHEMBL675231 0.70 GABRA1 (0.44) ALDH1A1KDM4EGMNNLMNACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8895744-B2 Alfa-carboline inhibitors of NPM-ALK, RET, and Bcr-Abl UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA (IT) 2014-11-25 US disclosed
US-20110281862-A1 ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) 2011-11-17 US disclosed
EP-2161271-A1 Alpha-carboline inhibitors of NMP-ALK, RET, and Bcr-Abl Università Degli Studi Di Milano - Bicocca (IT) 2010-03-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281862-A1 ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL ALK, BCR, NPM1 ALDH1A1 749/4885BRD4 944/4885KDM4E 2789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.